Pediatric Nirmatrelvir/Ritonavir Prescribing Patterns During the COVID-19 Pandemic.

Seuli Bose BrillKathryn HirabayashiNathan M Pajor Suchitra Rao Asuncion Mejias Ravi Jhaveri Christopher B Forrest L Charles Bailey Dimitri A Christakis Deepika Thacker Patrick C HanleyPayal B PatelJonathan D Cogen Jason P Block Priya Prahalad Vitaly LormanGrace M Lee

Published in: medRxiv : the preprint server for health sciences (2022)

Clinicians prescribe nirmatrelvir/ritonavir infrequently to children. While individuals receiving nirmatrelvir/ritonavir generally have significant chronic disease burden, a majority are receiving nirmatrelvir/ritonavir prescriptions without an EHR-recorded COVID-19 positive test or diagnosis. Development and implementation of concerted pediatric nirmatrelvir/ritonavir prescribing workflows can help better capture COVID-19 presentation, response, and adverse events at the population level.

Keyphrases

antiretroviral therapy
primary care
coronavirus disease
sars cov
young adults
emergency department
risk factors
quality improvement
case report